Palbociclib and INCMGA00012 in People With Advanced Liposarcoma

NCT04438824 | Active Not Recruiting Phase 2 FDA Drug

• 2 other identifiers: 20-062R01FD007528-01
• Study Type: interventional
• Target: 42
• Locations: 1 country
• Sites: 7

Brief Summary

The researchers are doing this study to find out whether combining the study drugs palbociclib and INCMGA00012 is an effective and safe treatment for advanced liposarcoma. "Funding Source - FDA OOPD"

Conditions

Well-differentiated/Dedifferentiated Liposarcoma

Keywords

Palbociclib; INCMGA00012; 20-062

Outcome Measures

Primary Outcomes (2)

• confirm the recommended phase two dose (RP2D

  DLTs will be assess within the first 6 weeks of the treatment combination . DLT definitions are described in section 15.4, and will be defined using NCI CTCAE v 5.0. If ≤ 1 patient out of 6 has a dose-limiting toxicity, the dosing used in the safety lead-in phase will be declared the recommended phase 2 dose. If ≥ 2 of 6 patients in the safety lead-in experience a DLT, study treatment will be halted and no further patients will be enrolled. If the study is resumed with an alternative dosing schema, a new safety lead-in phase will be completed with the new dosing regimen

  within 6 weeks of treatment

• best overall response rate (Phase II)

  defined by RECIST 1.1

  by 48 weeks

Secondary Outcomes (2)

• Safety

  2 years

• overall response rate

  48 weeks

Study Arms (1)

Palbociclib and INCMGA00012

EXPERIMENTAL

Initial design (safety lead-in and expansion): One treatment cycle will consist of 28 days. Patients in both study phases will start palbociclib on Day 1 and INCMGA00012 on day 15 (+/- 7 days) of each cycle at the following dose schedule: INCMGA00012: 500 mg IV (flat dose) q28 days Palbociclib: 125 mg PO daily for 21 days, followed by 7 days off, q28 days Palbociclib will be taken on Day 1 of each cycle for 21 consecutive days followed by 7 days off (days 22-28 of each Cycle). INCMGA00012 will be administered on Day 15 of (+/- 7 days) each cycle and repeat every 28 days.(No longer using this) Amended design (Expansion only): One treatment cycle will consist of 28 days. Patients in both study phases will start palbociclib and INCMGA00012 on day 1 of each cycle: 500 mg IV (flat dose) of INCMGA00012 will be administered q28 days concurrently with palbociclib 125 mg PO daily for 21 days, followed by 7 days off, q28 days.

Drug: INCMGA00012; Drug: Palbociclib

Interventions

INCMGA00012 DRUG

INCMGA00012: 500 mg IV (flat dose) q28 days (+/- 7 days in each cycle)

Palbociclib and INCMGA00012

Palbociclib DRUG

Palbociclib:125 mg PO daily for 21 days, followed by 7 days off, q28 days

Palbociclib and INCMGA00012

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• A diagnosis of metastatic or unresectable WD/DD liposarcoma. DD liposarcoma must be present. Unresectable is defined as if the primary tumor a) cannot be safely removed surgically or b) would benefit from systemic therapy prior to a surgical approach
• Measurable disease by RECIST 1.1
• a. Target lesions must not be chosen from a previously irradiated field unless there has been radiographically and/or pathologically documented tumor progression in that lesion prior to enrollment
• Age ≥ 18 years
• ECOG performance status 0 or 1
• Adequate organ and marrow function as defined below (ULN indicates institutional upper limit of normal):
• Absolute neutrophil count ≥ 1.5 x 109/L
• Hemoglobin ≥ 8.0 g/dL
• WBC ≥ 3.0 x 109/L
• Platelets ≥ 100 x 109/L
• ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN for subjects with total bilirubin levels \> 1.5 ULN. Except patients with Gilbert's disease (≤3x ULN)
• AST (SGOT) /ALT (SGPT) ≤ 3 x institutional ULN
• Creatinine Clearance \> 30 mL/min (calculated by Cockcroft-Gault method)
• Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) during the trial period through at least 120 days after the last dose of study treatment.
• Ability to understand and the willingness to sign a written informed consent document.

You may not qualify if:

• Patients who have not recovered from clinically significant adverse events of prior therapy to ≤ NCI CTCAE v5 Grade 1, except alopecia and stable neuropathy, which must have resolved to Grade ≤ 2 or baseline.
• Patients receiving any other investigational agents.
• Patients who have received prior treatment with a selective CDK4 inhibitor or an anti-PD-1/PD-L1 agent
• Uncontrolled intercurrent illness including, but not limited to, known ongoing or active infection, including uncontrolled HIV, active hepatitis B or C, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmias, psychiatric illness/social situations that would limit compliance with study requirements, clinically significant interstitial lung disease or active noninfectious pneumonitis, or active infection requiring systemic therapy
• Patients with NYHA class III or IV congestive heart failure within 6 months of study treatment will be excluded
• Pregnant women and women who are breast-feeding.
• History or evidence of symptomatic autoimmune disease in past 2 years prior to enrollment.
• a. Replacement therapy (e.g., thyroxine for hypothyroidism, insulin for diabetes or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment for autoimmune disease
• Prolonged QTcF \> 450 ms for men and \> 470 ms for women at Screening.
• Patients who have received a live vaccine within 30 days of the start date of the planned study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines are live attenuated vaccines, and are not allowed
• Radiation therapy within 2 weeks prior to study Day 1
• Prior organ transplantation including allogenic stem-cell transplantation
• Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v 5 Grade ≥ 3)
• Patients who require concomitant use of medications that strongly induce or inhibit CYP3A (per section 15.0)

Sponsors & Collaborators

• Memorial Sloan Kettering Cancer Center: lead
• Incyte Corporation: collaborator

Study Sites (7)

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)

Basking Ridge, New Jersey, 07920, United States

Location

Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

Middletown, New Jersey, 07748, United States

Location

Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Montvale, New Jersey, 07645, United States

Location

Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)

Commack, New York, 11725, United States

Location

Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Harrison, New York, 10604, United States

Location

Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States

Location

Memorial Sloan Kettering Nassau (Limited protocol activities)

Rockville Centre, New York, 11553, United States

Location

Related Links

• Memorial Sloan Kettering Cancer Center

MeSH Terms

Conditions

Liposarcoma

Interventions

palbociclib

Condition Hierarchy (Ancestors)

Neoplasms, Adipose Tissue; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms; Sarcoma

Study Officials

• Sandra D'Angelo, MD

  Memorial Sloan Kettering Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: This is a phase II study of palbociclib plus INCMGA00012 in patients with advanced WD/DD liposarcoma.

Study Record Dates

• First Submitted: June 17, 2020
• First Posted: June 19, 2020
• Study Start: June 17, 2020
• Primary Completion (Estimated): June 1, 2026
• Study Completion (Estimated): June 1, 2026
• Last Updated: October 14, 2025

Record last verified: 2025-10

Data Sharing

• IPD Sharing: Will share

Locations

US (7)